KDIGO 2026 Updates: Better Management of Anemia in CKD
Managing anemia in CKD requires clinicians to balance symptom relief against cardiovascular safety. Recently, Kidney Disease: Improving Global Outcomes released its 2026 clinical practice guideline update. Therefore, clinicians now have refined, evidence-based recommendations for evaluating and treating affected individuals.
Evaluating Iron Status in Anemia in CKD
First, clinicians must exclude reversible causes of hematologic decline before initiating specialized therapies. Consequently, comprehensive initial testing must assess nutritional deficiencies, occult blood loss, and systemic inflammation.
Additionally, the guideline establishes clear ferritin and transferrin saturation thresholds. In patients on hemodialysis, doctors should administer intravenous iron proactively rather than oral formulations. Furthermore, treating physicians must withhold iron when transferrin saturation reaches 40% or ferritin exceeds 700 ng/mL.
Erythropoietin-Stimulating Agents Versus HIF-PHIs
Importantly, the guideline prioritizes erythropoiesis-stimulating agents over hypoxia-inducible factor-prolyl hydroxylase inhibitors as first-line therapy. While oral agents offer convenience, extensive trial data confirm the established safety profile of conventional agents.
However, clinicians can consider oral inhibitors when patients cannot tolerate injections or lack medication refrigeration. Moreover, prescribers must avoid these agents in patients with active malignancy or recent thromboembolic complications.
Targeting Safe Hemoglobin Levels
When starting erythropoiesis-stimulating agents, physicians should personalize hemoglobin initiation thresholds. For instance, treatment decisions must reflect specific symptoms, functional demands, and cardiovascular risks rather than arbitrary laboratory numbers alone.
Furthermore, the guideline establishes an explicit upper hemoglobin limit. Therefore, clinicians must not use medical therapy to maintain hemoglobin levels above 11.5 g/dL. Exceeding this upper ceiling increases the risk of stroke, vascular thrombosis, and death.
Frequently Asked Questions
Q1: Why does the guideline prefer erythropoiesis-stimulating agents over HIF-PHIs?
Extensive clinical trial data confirm the long-term efficacy and safety profile of conventional agents. Therefore, guidelines recommend conventional agents as primary therapy unless specific barriers prevent their administration.
Q2: What is the recommended upper limit for hemoglobin target levels?
Clinicians should avoid maintaining hemoglobin concentrations above 11.5 g/dL. Exceeding this boundary significantly increases risks of serious thromboembolic events and vascular complications.
Q3: When should clinicians consider intravenous iron in dialysis patients?
Nephrologists should initiate proactive intravenous iron when transferrin saturation falls to 30% or ferritin drops below 500 ng/mL. However, teams should withhold iron if acute infection occurs.
For further professional upskilling in related fields, practitioners can explore comprehensive training via the Internal Medicine Speciality Courses.
References
- Hedayati SS et al. Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline. Ann Intern Med. 2026 Sep 15. doi: 10.7326/ANNALS-26-02326. PMID: 42735412.
- Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int. 2026;109(Suppl 1S):S1-S99.
- European Renal Best Practice (ERBP). KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2026;41(7):gfag014.
